585 results on '"Brinkmalm, Gunnar"'
Search Results
2. CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease
3. Optimal blood tau species for the detection of Alzheimer’s disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study
4. Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry
5. Differential effects of familial Alzheimer’s disease-causing mutations on amyloid precursor protein (APP) trafficking, proteolytic conversion, and synaptogenic activity
6. Specific Mutations in the Cholesterol-Binding Site of APP Alter Its Processing and Favor the Production of Shorter, Less Toxic Aβ Peptides
7. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
8. Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot study
9. Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry
10. Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
11. Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
12. Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain
13. Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains
14. Cerebrospinal fluid brevican and neurocan fragment patterns in human traumatic brain injury
15. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
16. Tau protein profiling in tauopathies: a human brain study.
17. Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer's disease with APPdup and Down syndrome.
18. Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathy.
19. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
20. Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration
21. P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
22. Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus
23. A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimer’s disease
24. Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer’s disease pathology
25. Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis
26. Plasma p-tau212: antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology
27. Profiling amyloid‐β peptides as diagnostic biomarkers for cerebral amyloid angiopathy
28. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
29. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
30. Low-dose γ-secretase inhibition increases secretion of Aβ peptides and intracellular oligomeric Aβ
31. Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury
32. The phosphorylation cascade hypothesis of Alzheimer’s disease
33. Correction: Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain
34. Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies
35. Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
36. Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer’s disease patients
37. SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease.
38. Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
39. Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy
40. The aqueous phase of Alzheimer's disease brain contains assemblies built from ∼4 and ∼7 kDa Aβ species
41. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease
42. Explorative and targeted neuroproteomics in Alzheimer's disease
43. Tau protein profiling across brain of different tauopathies using high‐resolution mass spectrometry: quantification of isoforms and phosphorylations
44. Simultaneous Mass Spectrometric quantification of multiple p‐tau species in plasma – findings along the Alzheimer´s disease continuum
45. Differential effects of familial Alzheimer’s disease-causing mutations on amyloid precursor protein (APP) trafficking, proteolytic conversion, and synaptogenic activity
46. Targeting Synaptic Pathology with a Novel Affinity Mass Spectrometry Approach
47. Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase
48. The presubiculum is preserved from neurodegenerative changes in Alzheimer’s disease
49. Chemical traits of cerebral amyloid angiopathy in familial British‐, Danish‐, and non‐Alzheimerʼs dementias
50. Genetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.